Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR17 | Q13304 | 2/20 | 0.53 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4159537 | 0.86 | MPO (0.43) | GPR17PARP1HPGDCYP2C19 | |
| SCHEMBL4153199 | 0.83 | GPR17 (0.54) | GPR17HPGDKDM4EMEN1KMT2A | |
| SCHEMBL4171570 | 0.83 | KDM4E (0.47) | GPR17PARP1HPGDCYP2C19KDM4E | |
| SCHEMBL4176378 | 0.81 | GPR17 (0.48) | GPR17PARP1HPGDS1PR1CYP2C19 | |
| SCHEMBL3244302 | 0.79 | F7 (0.52) | PARP1HPGDKDM4EMEN1LMNA | |
| SCHEMBL4169910 | 0.79 | HPGD (0.44) | GPR17PARP1HPGDCYP2C19KDM4E | |
| SCHEMBL4165123 | 0.79 | HPGD (0.63) | GPR17PARP1HPGDCYP2C19MEN1 | |
| SCHEMBL4155432 | 0.79 | CYP2C19 (0.44) | GPR17PARP1HPGDCYP2C19KDM4E | |
| SCHEMBL4160621 | 0.79 | MPO (0.49) | GPR17HPGDCYP2C19KDM4EKMT2A | |
| SCHEMBL16540415 | 0.78 | GPR84 (0.61) | GPR17HPGDS1PR1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | claimed |
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | disclosed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | MAP3K1, MAP3K2, MAP3K7 | GPR17 2461/4885PARP1 628/4885HPGD 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.